Drug Profile

ABO 101 - Arbor Biotechnologies

Alternative Names: ABO-101 - Arbor Biotechnologies

Latest Information Update: 23 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arbor Biotechnologies
Class Gene therapies
Mechanism of Action Glycolate oxidase expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary hyperoxaluria type 1
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Primary hyperoxaluria type 1

Most Recent Events

13 May 2025 Preclinical trials in Primary hyperoxaluria type 1 in United Kingdom (IV) before May 2025
13 May 2025 Arbor Biotechnologies receives IND approval for ABO 101 in United Kingdom
13 May 2025 Pharmacodynamics and adverse events data from preclinical studies trial in Primary hyperoxaluria 1 released by Arbor Biotechnologies

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com